Friday's big stock stories: What’s likely to move the market in the next trading session

Cnbc · May 21, 2026 · 684 words · By Jason Gewirtz

Market Analysis Financial Education Promotion

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Market Analysis

Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and last look at today.

Claims checked 44

Techniques found 2

Topics 2

Coverage spectrum

Coverage gap: Low Right coverage

Left50%

Center50%

Right0%

2 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and last look at today.

Why it matters

Common ground

Here's what CNBC TV's producers were watching and what's on the radar for the next session.

Perspective signals

The tension in the story is sharpened by Loaded Language, Glittering Generalities: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Market Analysis story?
What evidence would most clearly confirm or weaken the claim that It's down 21% from the 52-week high reached in July?
How does this story connect Market Analysis with Financial Education Promotion over the next few days?

open_in_new Read the original article: https://www.cnbc.com/2026/05/21/fridays-big-stock-stories-whats-likely-to-move-t…

psychologyPropaganda Techniques Detected

eFinder identified 2 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 70% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Glittering Generalities 60% confidence

Using vague, emotionally appealing phrases ('freedom', 'justice') without specifics.

Why it matters: Recognizing glittering generalities helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 44 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 34

info Single Source 6

help Insufficient Evidence 3

cancel Disputed 1

schedule

Claim 1: “It's down 21% from the 52-week high reached in July.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 2: “It has gained about 33% in the past year.”

SINGLE SOURCE

Search results confirm the index exists and provide links to historical data, but the specific figure of a 33% gain over the past year is not present in the provided evidence snippets.

travel_explore

web search NEUTRAL — Get historical data for the NYSE Arca Biotechnology Index (^BTK) on Yahoo Finance. View and download daily, weekly or monthly data to help your investment decisions.
https://finance.yahoo.com/quote/^BTK/history/

travel_explore

web search NEUTRAL — Overvalued Stocks. ARCA Biotechnology (BTK). Find here information about the ARCA Biotechnology index (BTK). Assess the ARCA Biotechnology stock price and overall performance.
https://www.investing.com/indices/arca-biotechnology

travel_explore

web search NEUTRAL — BTK | A complete NYSE Arca Biotechnology Index index overview by MarketWatch. View stock market news, stock market data and trading information.
https://www.marketwatch.com/investing/index/btk

schedule

Claim 3: “Crown Castle has added 6.2% week to date.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 4: “It is down 62% from the October high.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 5: “Rigetti Computing is up again after hours, almost 7%.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 6: “Its business focuses on leasing land for cell phone towers.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 7: “The stock has a current dividend yield of about 3.8%.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

cancel

Claim 8: “The influential meeting of the American Society of Clinical Oncology begins on Friday.”

DISPUTED

The evidence provides conflicting dates for the ASCO meeting. One source states it was scheduled for May 29 to June 2, while another states it takes place June 3–7. This contradicts the claim that it begins on 'Friday' without a specific date, as the start dates vary across sources.

travel_explore

web search NEUTRAL — Make JCO Central your hub to recharge, network, and engage in editor-led education. Learn publishing best practices, explore global oncology trends, and connect daily with our editorial team.
https://www.asco.org/

travel_explore

web search NEUTRAL — Due to COVID-19 (coronavirus), the American Society of Clinical Oncology (ASCO) Annual Meeting will now occur using a virtual format instead of the in-person meeting that had been scheduled to take pl…
https://www.onclive.com/view/asco-meeting-goes-virtual-due-t…

travel_explore

web search NEUTRAL — Among those presenting at this year's American Society of Clinical Oncologists meeting are physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center. The meeting takes…
https://www.newswise.com/articles/newyork-presbyterian-colum…

schedule

Claim 9: “The stock jumped almost 20% during the regular session.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 10: “It's little changed in May, and has gained about 39% in a year.”

INSUFFICIENT EVIDENCE

No evidence was found for this claim in the provided search results.

schedule

Claim 11: “The stock is down 20% from the July high.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 12: “It is off 73% from the October high.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 13: “It is down 22% from the November high.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 14: “The company is a competitor of American Tower.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 15: “Much of the business is invested in labs leased to clients in the life sciences industry.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 16: “The index is down 5.25% from the January high.”

SINGLE SOURCE

The evidence provides general overviews and chart links for the .BTK index, but does not state the specific percentage drop from the January high.

travel_explore

web search NEUTRAL — Find the latest information on NYSE Arca Biotechnology Index (^BTK) including data, charts, related news and more from Yahoo Finance.
https://finance.yahoo.com/quote/^BTK/

travel_explore

help

Claim 17: “It has gained 67% in the past year.”

INSUFFICIENT EVIDENCE

The claim states a 67% gain in the past year, but a specific news source (24/7 Wall St.) explicitly states that the XBI gained +40.32% over the past year, directly contradicting the 67% figure.

travel_explore

web search NEUTRAL — State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) retur…
https://247wallst.com/investing/2026/03/31/biotech-stocks-ar…

travel_explore

web search NEUTRAL — Find the latest State Street SPDR S&P Biotech ETF (XBI) stock quote, history, news and other vital information to help you with your stock trading and investing.Locking In A Quick Gain In This Biotech…
https://finance.yahoo.com/quote/XBI/

travel_explore

web search NEUTRAL — | XBI U.S.: NYSE Arca. State Street SPDR S&P Biotech ETF.Locking In A Quick Gain In This Biotech ETF Made Room For Better Swing Trades; Here's Why.
https://www.marketwatch.com/investing/fund/xbi

schedule

Claim 18: “It is off 38% from the October high.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 19: “American Tower has gained 7.7% in the past four days.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 20: “The ETF is up 1% in May.”

SINGLE SOURCE

The evidence mentions the XBI ETF and some technical analysis, but does not confirm a 1% increase in May.

travel_explore

web search NEUTRAL — Find the latest State Street SPDR S&P Biotech ETF (XBI) stock quote, history, news and other vital information to help you with your stock trading and investing.Inception Date. More about State Street…
https://finance.yahoo.com/quote/XBI/

travel_explore

web search NEUTRAL — About State Street SPDR S&P Biotech ETF.Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly. Prior to Oct. 31, 2025 …
https://www.tradingview.com/symbols/AMEX-XBI/

travel_explore

web search NEUTRAL — Top Stories On State Street SPDR S&P Biotech ETF.May. 1, 2026 at 3:08 p.m. ET by Investor's Business Daily. Technical Analysis Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% F…
https://www.marketwatch.com/investing/fund/xbi

info

Claim 21: “The State Street SPDR S & P Biotech ETF (XBI) is down 4.6% from the April 17 high.”

SINGLE SOURCE

The evidence confirms the existence of the XBI ETF, but does not provide the specific percentage decrease from the April 17 high.

travel_explore

web search NEUTRAL — Find the latest State Street SPDR S&P Biotech ETF (XBI) stock quote, history, news and other vital information to help you with your stock trading and investing.This Biotech ETF Is Still Well Below It…
https://finance.yahoo.com/quote/XBI/

travel_explore

web search NEUTRAL — Get detailed information about the SPDR S&P Biotech ETF. View the current XBI stock price chart, historical data, premarket price, dividend returns and more.
https://www.investing.com/etfs/spdr-s-p-biotech

travel_explore

web search NEUTRAL — Key Features. The State Street® SPDR® S&P® Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P® Biotechnolog…
https://www.ssga.com/us/en/intermediary/etfs/state-street-sp…

info

Claim 22: “The NYSE Arca Biotechnology Index (.BTK) is up nearly 4% in May.”

SINGLE SOURCE

While web results confirm the existence of the NYSE Arca Biotechnology Index (.BTK), none of the provided search results contain the specific percentage change for the month of May.

travel_explore

schedule

Claim 23: “IonQ was up 12% on Thursday.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 24: “Quantum Computing is up 5% after hours.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 25: “D-Wave Quantum is up 7% after hours.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 26: “The Pharma, Biotech and Life Sciences S & P Industry Group is off 7.5% from the February high.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 27: “Alexandria Real Estate has advanced 6.4% in four days.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 28: “The current dividend yield is 4.6%.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 29: “The S & P Real Estate sector has added about 3% in four days.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 30: “IBM is in the space, too. It was up 12% during the session.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 31: “The S & P Real Estate Sector has risen about 11% in a year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 32: “It has advanced 1% in a month, and it has gained around 13% in a year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 33: “The stock is down 30% from the October high.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 34: “The S & P 500 has jumped 27% in a year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 35: “Shares are down 46% from the 52-week high hit in September.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 36: “Arqit Quantum was up 25% in the session.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 37: “S & P Health Care Sector, which is down 7.5% from the February high.”

INSUFFICIENT EVIDENCE

No evidence was found for this claim in the provided search results.

schedule

Claim 38: “The stock is down 45% from the October high.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 39: “The stock has a current yield of 8.5%.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 40: “The stock picked up 30% in regular trading.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 41: “The iShares Biotechnology ETF (IBB) is off 6% from the January high.”

SINGLE SOURCE

The evidence confirms the existence and purpose of the IBB ETF, but does not provide the specific percentage drop from the January high.

travel_explore

web search NEUTRAL — The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.Current performance may be lower or higher than the perform…
https://www.ishares.com/us/products/239699/ishares-biotechno…

travel_explore

web search NEUTRAL — iShares Biotechnology ETF Overview iShares / Health. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its asset…
https://finance.yahoo.com/quote/IBB/

travel_explore

web search NEUTRAL — Get detailed information about the iShares Biotechnology ETF ETF. View the current IBB stock price chart, historical data, premarket price, dividend returns and more.
https://www.investing.com/etfs/ishares-nasdaq-biotech

schedule

Claim 42: “It has jumped 27% in a year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 43: “The stock was up 33% on Thursday.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 44: “the U.S. government said it was giving $2 billion to a group of companies in the quantum computing space.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.